{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:05:55Z","timestamp":1780355155094,"version":"3.54.1"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To assess the role of consolidating adjuvant therapy for cavitary retinoblastoma and to understand if there is any phenotype\u2013genotype correlation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Patients with retinoblastomas having ophthalmoscopically visible cavities between 2004 and 2014 in whom 4 to 6 cycles of systemic chemotherapy were given.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Eighteen eyes of 17 patients displayed cavitary retinoblastomas. This represented 6.8% of 250 patients. Mean age at diagnosis was 13 months; 5 unilateral (29%) and 12 bilateral (71%). The mean (median, range) number of retinoblastoma tumors per eye was 2 (2; 1\u20136). The number of cavities per tumor was 3 (2, 1\u20136). Intratumoral cavities were seen in the superficial portion of the tumor in 10 eyes (55%). The cavities became visible in eight eyes (44%) and collapsed in eight eyes (44%). Two eyes required enucleation because of relapse in noncavitary tumors. Germline mutations were detected in 14 patients (82%) of whom four demonstrated mosaicism (29%); only one had a low penetrant mutation. The mean follow-up period was 40 (35, 6\u2013120) months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Cavitary retinoblastomas can be detected after systemic chemotherapy with cavities becoming visible after mean two cycles of chemotherapy (secondary cavitary retinoblastoma). The etiology is uncertain. They remain stable and do not require aggressive adjuvant therapy. There was no evident phenotype\u2013genotype correlation with mosaicism noted in 29%.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000001597","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T13:20:17Z","timestamp":1490966417000},"page":"782-787","source":"Crossref","is-referenced-by-count":10,"title":["THE RECOGNITION OF CAVITARY RETINOBLASTOMA TUMORS"],"prefix":"10.1097","volume":"38","author":[{"given":"Shabana","family":"Chaudhry","sequence":"first","affiliation":[{"name":"Retinoblastoma Unit, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom;"},{"name":"Pediatrics and Ocular Oncology Services, Moorfields Eye Hospital, London, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zerrin","family":"Onadim","sequence":"additional","affiliation":[{"name":"Retinoblastoma Unit, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep S.","family":"Sagoo","sequence":"additional","affiliation":[{"name":"Retinoblastoma Unit, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom;"},{"name":"Pediatrics and Ocular Oncology Services, Moorfields Eye Hospital, London, United Kingdom; and"},{"name":"National Institute for Health Research Biomedical Research Centre, UCL Institute of Ophthalmology, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Ashwin","family":"Reddy","sequence":"additional","affiliation":[{"name":"Retinoblastoma Unit, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom;"},{"name":"Pediatrics and Ocular Oncology Services, Moorfields Eye Hospital, London, United Kingdom; and"},{"name":"National Institute for Health Research Biomedical Research Centre, UCL Institute of Ophthalmology, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230817","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ophtha.2005.01.041","article-title":"Cavitary changes in retinoblastoma: relationship to chemoresistance","volume":"112","author":"Mashayekhi","year":"2005","journal-title":"Ophthalmology"},{"key":"R3-20230817","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/archopht.126.11.1598","article-title":"Cavitary retinoblastoma: ultrasonographic and fluorescein angiographic findings in 3 cases","volume":"126","author":"Palamar","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"R4-20230817","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/00006982-200412000-00003","article-title":"Continuing challenges in the management of retinoblastoma with chemotherapy","volume":"24","author":"Shields","year":"2004","journal-title":"Retina"},{"key":"R5-20230817","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/bjo.86.1.80","article-title":"Retinoblastoma treated with primary chemotherapy alone. The significance of tumor size, location and age","volume":"86","author":"Gombos","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"R7-20230817","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archophthalmol.2011.2825","article-title":"Intravenous chemoreduction or intra-arterial chemotherapy for cavitary retinoblastoma: long-term results","volume":"130","author":"Rojanaporn","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"R9-20230817","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3928\/0191-3913-20030701-05","article-title":"Trends in the management of retinoblastoma: evaluation of 1.196 consecutive eyes during 1974\u20132001","volume":"40","author":"Epstein","year":"2003","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"R10-20230817","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0002-9394(70)92263-4","article-title":"The nature of retinoblastoma, I: photoreceptor differentiation: a clinical and histopathologic study","volume":"69","author":"Ts'o","year":"1970","journal-title":"Am J Ophthalmol"},{"key":"R11-20230817","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1136\/jmedgenet-2013-101821","article-title":"Spectrum of RB1 mutations identified in 403 retinoblastoma patients","volume":"51","author":"Price","year":"2014","journal-title":"J Med Genet"},{"key":"R12-20230817","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ohc.2004.11.003","article-title":"Intraocular retinoblastoma: the case for a new group classification","volume":"18","author":"Linn Murphree","year":"2005","journal-title":"Ophthalmol Clin North Am"},{"key":"R13-20230817","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/archopht.1996.01100140530002","article-title":"Chemoreduction in the initial management of intraocular retinoblastoma","volume":"114","author":"Shields","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"R14-20230817","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3928\/0191-3913-20020301-11","article-title":"Lack of response to chemoreduction in presumed well differentiated retinoblastoma","volume":"39","author":"Singh","year":"2002","journal-title":"J Pediatr Strabismus"},{"key":"R15-20230817","first-page":"465","article-title":"Retinoma underlying retinoblastoma revealed after tumor response to 1 cycle of chemotherapy","volume":"100","author":"Dimaras","year":"2009","journal-title":"Cancer Sci"},{"key":"R16-20230817","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/13816819109029394","article-title":"Retinoma: case studies","volume":"12","author":"Balmer","year":"1991","journal-title":"Ophthalmic Paediatr Genet"},{"key":"R17-20230817","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.5858\/133.8.1203","article-title":"High-risk features and tumor differentiation in retinoblastoma: a retrospective histopathologic study","volume":"133","author":"Eagle","year":"2009","journal-title":"Arch Pathol Lab Med"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006982-201804000-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T01:00:54Z","timestamp":1692234054000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201804000-00019"}},"subtitle":["Implications for Management and Genetic Analysis"],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000001597","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}